Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 0.78.

  • Nurix Therapeutics' Equity Ratio fell 56.14% to 0.78 in Q4 2025 from the same period last year, while for Nov 2025 it was 0.78, marking a year-over-year decrease of 56.14%. This contributed to the annual value of 0.78 for FY2025, which is 56.14% down from last year.
  • Nurix Therapeutics' Equity Ratio amounted to 0.78 in Q4 2025, which was down 56.14% from 0.71 recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Equity Ratio high stood at 0.79 for Q4 2024, and its period low was 0.54 during Q1 2024.
  • Moreover, its 5-year median value for Equity Ratio was 0.74 (2023), whereas its average is 0.72.
  • As far as peak fluctuations go, Nurix Therapeutics' Equity Ratio tumbled by 2710.52% in 2024, and later skyrocketed by 4488.31% in 2025.
  • Over the past 5 years, Nurix Therapeutics' Equity Ratio (Quarter) stood at 0.72 in 2021, then grew by 1.5% to 0.73 in 2022, then dropped by 22.63% to 0.56 in 2023, then soared by 39.64% to 0.79 in 2024, then decreased by 0.56% to 0.78 in 2025.
  • Its Equity Ratio was 0.78 in Q4 2025, compared to 0.71 in Q3 2025 and 0.76 in Q2 2025.